Akasaki Y, Kikuchi T, Homma S, Abe T, Kofe D, Ohno T
Department of Neurosurgery, Jikei University School of Medicine, Tokyo, Japan.
J Immunother. 2001 Mar-Apr;24(2):106-13.
The authors studied antitumor immunity conferred by fusions of dendritic and glioma cells in a mouse brain tumor model. Previous immunization with fusion cells (FCs) prevented tumor formation on challenge with glioma cells in the flank or in the brain. Efficacy was decreased when studies were performed in mice depleted of CD8+ cells. In a treatment model, FCs were injected subcutaneously after tumor development in the brain. The administration of FCs alone had limited effects on survival of mice bearing brain tumors. Importantly, however, administration of FCs and recombinant interleukin-12 (rIL-12) remarkably prolonged the survival of mice with brain tumors. Cytotoxic T lymphocyte activity against glioma cells from immunized mice was also stimulated by coadministration of FCs and rIL-12 compared with that obtained with FCs or rIL-12 alone. These data support the therapeutic efficacy of combining FC-based vaccine therapy and rIL-12.
作者在小鼠脑肿瘤模型中研究了树突状细胞与胶质瘤细胞融合所赋予的抗肿瘤免疫力。先前用融合细胞（FCs）进行免疫可预防在侧腹或脑内接种胶质瘤细胞时肿瘤的形成。当在耗尽CD8 +细胞的小鼠中进行研究时，疗效降低。在一个治疗模型中，在脑内肿瘤形成后皮下注射FCs。单独给予FCs对患有脑肿瘤的小鼠的存活影响有限。然而，重要的是，给予FCs和重组白细胞介素-12（rIL-12）可显著延长患有脑肿瘤小鼠的存活时间。与单独使用FCs或rIL-12相比，联合给予FCs和rIL-12还可刺激免疫小鼠对胶质瘤细胞的细胞毒性T淋巴细胞活性。这些数据支持基于FCs的疫苗疗法与rIL-12联合使用的治疗效果。
